FimmCyte
We a novel first in-class treatment for Endometriosis based on the immune system.
Total raised
€1.2M
€1,202,003
Funding rounds
2
Investors
2
distinct backers
Active since
2022-07
latest 2024-02
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood18
base rate 45% for Debt
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood12
base rate 12% (2+ rounds)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-02-29 | Debt | €1.0M | UZH Life Sciences Fund (LSF) | View deal → |
| 2022-07-13 | Other | €152k | Venture Kick | View deal → |
Investors
2Related news
- FimmCyte obtains CHF 150’000 to tackle Endometriosisstartupticker.ch · 2022-07
- startupticker.ch
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy